Masarov (Acetylsalicylic Acid, Rosuvastatin)

Masarov, a combination of an antiplatelet agent and a statin, is employed within the cardiovascular disease prevention pathway.

• Secondary prevention of myocardial infarction: reduces the risk of recurrent heart attacks and related complications.
• Secondary prevention of ischemic stroke: lowers the likelihood of subsequent strokes in patients with prior cerebrovascular events.
• Hyperlipidaemia management: decreases LDL‑cholesterol and total cholesterol levels to improve lipid profiles.

• Acetylsalicylic acid irreversibly inhibits cyclo‑oxygenase‑1 in platelets, suppressing thromboxane A2 synthesis and thereby reducing platelet aggregation. Rosuvastatin competitively blocks HMG‑CoA reductase, the rate‑limiting enzyme in hepatic cholesterol biosynthesis, leading to lowered LDL‑cholesterol, up‑regulation of LDL receptors, and overall improvement of lipid metabolism. The combined antiplatelet and lipid‑lowering actions synergistically diminish atherothrombotic risk and support vascular health and contribute to secondary prevention of cardiovascular events.

Masarov may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Gastrointestinal irritation: dyspepsia, abdominal discomfort, or nausea.
• Headache: mild to moderate head pain.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: mild increases in ALT or AST.

Serious or Rare Side Effects

• Gastrointestinal bleeding: severe hemorrhage or melena.
• Hemorrhagic stroke: intracranial bleeding events.
• Severe allergic reactions: anaphylaxis or angioedema.
• Rhabdomyolysis: muscle breakdown with risk of renal injury.
• Liver failure: acute hepatic dysfunction.
• Stevens‑Johnson syndrome: serious skin and mucosal reactions.

When prescribing Masarov, clinicians should consider several precautionary measures to ensure safe use.

• Assess bleeding risk: evaluate history of ulcers, hemorrhage, or concurrent anticoagulant therapy.
• Monitor liver function: check baseline ALT/AST and repeat during treatment.
• Evaluate renal function: adjust use in patients with severe renal impairment.
• Avoid in known hypersensitivity: do not use in patients allergic to aspirin, NSAIDs, or rosuvastatin.
• Caution in pregnancy and lactation: use only if potential benefit justifies risk.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Masarov can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Other NSAIDs or aspirin-containing products: additive antiplatelet effect leading to hemorrhage.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise rosuvastatin plasma levels, risk of myopathy.
• Gemfibrozil or other fibrates: heightened risk of rhabdomyolysis.
• Methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: possible additive blood pressure lowering.
• Antidiabetic drugs: statins may modestly affect glucose control.